A	0	0
general	2	8
strategy	10	17
for	19	21
the	23	25
bacterial	27	35
expression	37	46
of	48	49
amyloidogenic	51	63
peptides	65	72
using	74	78
BCL	80	82
-	83	83
XL	84	85
-	86	86
1	87	87
/	88	88
2	89	89
fusions	91	97
.	98	98

Biophysical	100	110
studies	112	118
on	120	121
amyloidogenic	123	135
and	137	139
aggregation	141	151
-	152	152
prone	153	157
peptides	159	166
often	168	172
require	174	180
large	182	186
quantities	188	197
of	199	200
material	202	209
.	210	210

However	212	218
,	219	219
solid	221	225
-	226	226
phase	227	231
synthesis	233	241
,	242	242
handling	244	251
,	252	252
and	254	256
purification	258	269
of	271	272
peptides	274	281
often	283	287
present	289	295
challenges	297	306
on	308	309
these	311	315
scales	317	322
.	323	323

Recombinant	325	335
expression	337	346
is	348	349
an	351	352
attractive	354	363
alternative	365	375
because	377	383
of	385	386
its	388	390
low	392	394
cost	396	399
,	400	400
the	402	404
ability	406	412
to	414	415
isotopically	417	428
label	430	434
the	436	438
peptides	440	447
,	448	448
and	450	452
access	454	459
to	461	462
sequences	464	472
exceeding	474	482
approximately	484	496
50	498	499
residues	501	508
.	509	509

However	511	517
,	518	518
expression	520	529
systems	531	537
that	539	542
seek	544	547
to	549	550
solubilize	552	561
amyloidogenic	563	575
peptides	577	584
suffer	586	591
from	593	596
low	598	600
yields	602	607
,	608	608
difficult	610	618
optimizations	620	632
,	633	633
and	635	637
isolation	639	647
challenges	649	658
.	659	659

We	661	662
present	664	670
a	672	672
general	674	680
strategy	682	689
for	691	693
expressing	695	704
and	706	708
isolating	710	718
amyloidogenic	720	732
peptides	734	741
in	743	744
Escherichia	746	756
coli	758	761
by	763	764
fusion	766	771
to	773	774
a	776	776
polypeptide	778	788
that	790	793
drives	795	800
the	802	804
expression	806	815
of	817	818
attached	820	827
peptides	829	836
into	838	841
bacterial	843	851
inclusion	853	861
bodies	863	868
.	869	869

This	871	874
scheme	876	881
minimizes	883	891
toxicity	893	900
during	902	907
bacterial	909	917
growth	919	924
and	926	928
enables	930	936
the	938	940
processing	942	951
and	953	955
handling	957	964
of	966	967
the	969	971
peptides	973	980
in	982	983
denaturing	985	994
solutions	996	1004
.	1005	1005

Immobilized	1007	1017
metal	1019	1023
affinity	1025	1032
chromatography	1034	1047
,	1048	1048
reverse	1050	1056
phase	1058	1062
HPLC	1064	1067
,	1068	1068
and	1070	1072
cyanogen	1074	1081
bromide	1083	1089
cleavage	1091	1098
are	1100	1102
used	1104	1107
to	1109	1110
isolate	1112	1118
the	1120	1122
peptide	1124	1130
,	1131	1131
followed	1133	1140
by	1142	1143
further	1145	1151
reverse	1153	1159
phase	1161	1165
HPLC	1167	1170
,	1171	1171
which	1173	1177
yields	1179	1184
milligram	1186	1194
quantities	1196	1205
of	1207	1208
the	1210	1212
purified	1214	1221
peptide	1223	1229
.	1230	1230

We	1232	1233
demonstrate	1235	1245
that	1247	1250
driving	1252	1258
the	1260	1262
peptides	1264	1271
into	1273	1276
inclusion	1278	1286
bodies	1288	1293
using	1295	1299
fusion	1301	1306
to	1308	1309
BCL	1311	1313
-	1314	1314
XL	1315	1316
-	1317	1317
1	1318	1318
/	1319	1319
2	1320	1320
is	1322	1323
a	1325	1325
general	1327	1333
strategy	1335	1342
for	1344	1346
their	1348	1352
expression	1354	1363
and	1365	1367
isolation	1369	1377
,	1378	1378
as	1380	1381
exemplified	1383	1393
by	1395	1396
the	1398	1400
production	1402	1411
of	1413	1414
11	1416	1417
peptides	1419	1426
species	1428	1434
.	1435	1435
